Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease

BioTech 365

Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic Breast … Continue reading → Business Wire

HR 52

ENHERTU® Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease

BioTech 365

ENHERTU® Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease ENHERTU® Reduced the Risk of Disease Progression or Death by 50% vs. … Continue reading → Business Wire

HR 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2-Low Metastatic Breast Cancer with HR-Positive and HR-Negative Disease

BioTech 365

HR 52

Trodelvy® Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients

BioTech 365

HR 52

Global HR+/HER2-VE Breast Cancer Pipeline Landscape Report 2021 – ResearchAndMarkets.com

BioTech 365

Global HR+/HER2-VE Breast Cancer Pipeline Landscape Report 2021 – ResearchAndMarkets.com Global HR+/HER2-VE Breast Cancer Pipeline Landscape Report 2021 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “HR+/HER2-VE Breast Cancer – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. This HR+/HER2-VE Breast … Continue reading → Business Wire

HR 40

Calgary Dental HR Firm Enters Agreement with Global Dental Supplier to Provide HR Management Services

BioTech 365

Calgary Dental HR Firm Enters Agreement with Global Dental Supplier to Provide HR Management Services Calgary Dental HR Firm Enters Agreement with Global Dental Supplier to Provide HR Management Services CALGARY, Alberta–(BUSINESS WIRE)–#albertadentist–With businesses everywhere struggling to keep their doors … Continue reading → Business Wire

HR 40

Regional Business Leaders Warn of Tremendous Loss of Jobs, Economic Output from H.R. 3

BioTech 365

Regional Business Leaders Warn of Tremendous Loss of Jobs, Economic Output from H.R. 3 Regional Business Leaders Warn of Tremendous Loss of Jobs, Economic Output from H.R.

HR 52

SET2,3 index can be prognostic in HR+ breast cancer, independent of recurrence score

Scienmag

Credit: SWOG/The Hope Foundation In an analysis of data from postmenopausal patients with hormone receptor-positive breast cancer, a standard measure of gene expression known as the sensitivity-to-endocrine-therapy (SET2,3) index was found to have prognostic value that complemented the known prognostic value of the 21-gene breast recurrence score.

HR 82

Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer

BioTech 365

Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer With the MONALEESA-2 final analysis, only … Continue reading → GlobeNewswire

HR 52

Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-Line HR+/HER2- Metastatic Breast Cancer

The Pharma Data

Nasdaq: GILD) today announced results from the Phase 3 TROPiCS-02 study evaluating Trodelvy ® (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy.

HR 52

BioTalent Canada cements status as Canada’s voice for biotechnology HR with spot on list of Best Workplaces in Canada

BioTech 365

BioTalent Canada cements status as Canada’s voice for biotechnology HR with spot on list of Best Workplaces in Canada BioTalent Canada cements status as Canada’s voice for biotechnology HR with spot on list of Best Workplaces in Canada OTTAWA, Ontario–(BUSINESS … Continue reading → Business Wire

HR 52

Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

BioTech 365

Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i New data underscore efficacy … Continue reading → GlobeNewswire

HR 40

Can Your Employer Make You Get a Vaccine? A Conversation with an HR Consultant

BioSpace

We interviewed Krissy Fuller, a human resources consultant, to learn more about the issue of mandated vaccines from an HR perspective and shared her predictions on what changes she thinks will last after the pandemic

HR 61

First new drug in years reduces recurrence in high risk HR+ early breast cancer

Scienmag

Data from latest research presented at the ESMO Virtual Congress 2020 Lugano, Switzerland, 20 September 2020 – Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to results from a study […].

HR 58

FIRST-LINE IBRANCE® (PALBOCICLIB) COMBINATION THERAPY IN HR+, HER2- METASTATIC BREAST CANCER

The Pharma Data

months with letrozole alone (HR 0.58: 95% CI, 0.49 months among patients in the letrozole group (HR 0.66: 95% CI, 0.53 This real-world cohort includes more than 1,400 women with HR+, HER2- mBC with any extent of visceral disease.

HR 52

Piqray and Faslodex combo extends survival in HR+/HER2-, PIK3CA+ advanced breast cancer at ESMO 2020

The Pharma Data

New data has been unveiled for the combination of Novartis’ Piqray (alpelisib) with AstraZeneca’s Faslodex (fulvestrant) in the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer in patients whose tumours are PIK3CA positive.

HR 52

Increasing the Business Value of Your HR Data: Integrate to Innovate

XTalks

HR organizations rely on access to employee data to address regulatory requirements, support modernization projects, manage talent, and address mergers and acquisitions. Why is having the right HR technology so important?

HR 59

Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer

BioTech 365

Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer Results from pre-planned subgroup … Continue reading → GlobeNewswire

HR 40

Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020

BioTech 365

Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020 Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast … Continue reading → Business Wire

HR 52

Novartis Piqray(R) – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval

Pharma Mirror

The post Novartis Piqray(R) – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval appeared first on Pharma Mirror Magazine. Novartis announced the Health Sciences Authority (HSA) has approved* Piqray®, an ?-specific

HR 52

Novartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutation

BioTech 365

In SOLAR-1 final analysis, Piqray (alpelisib) plus fulvestrant demonstrated 8 months clinically relevant improvement in overall survival (OS) in HR+/HER2- advanced breast cancer (aBC) patients with a PIK3CA mutation compared to fulvestrant alone1 14+ months OS improvement was achieved in … Continue reading → GlobeNewswire

HR 40

How Has COVID-19 Changed the Way We Work in the Life Sciences?

XTalks

Xtalks spoke with two HR professionals to find out how companies are handling the transition from a work-from-home policy to a hybrid or back-to-work model. News Blogs Career Insights Blogs Featured Pandemic Highlight COVID-19 Life Science Jobs HR

Life Science Careers: Leveraging AI in Talent Acquisition and Industry Expertise for Employers and Employees

XTalks

Therefore, the role of HR is critical at any organization. And on February 19, join An Insider’s Look: How Syneos Health is Shortening the Distance from Lab to Life in Clinical Trials for key industry HR insights for jobseekers. This includes hiring practices and HR management.

NTU launches two new programs to develop human resource talent with Institute for Human Resource Professionals

Scienmag

Credit: NTU Singapore Nanyang Technological University, Singapore (NTU Singapore) is collaborating with the Institute for Human Resource Professionals (IHRP) to launch two new MiniMasters™ programmes to develop talent in human resources (HR).

HR 83

Gilead's Trodelvy Data Leaves Some Questioning Clinical Advantage

BioSpace

Gilead Sciences shared what seemed to be good news regarding Trodelvy in HR+/HER2- breast cancer at the 2022 American Society of Clinical Oncology's annual meeting

HR 57

20-year research breakthrough offers new hope for breast cancer patients

Scienmag

20-year research breakthrough offers new hope for high risk patients with HR+ breast cancer A new treatment for breast cancer patients with hormone receptor (HR+) early stage disease who are at a high risk of recurrence has been shown to reduce the risk by 25%, according to a study led by The Royal Marsden NHS […].

HR 63

Saliva testing may allow early detection of human papillomavirus–driven head and neck cancers

Scienmag

Philadelphia, September 21, 2021 – Cancer causing high-risk human papillomaviruses (HR-HPV) are responsible for the rising incidence of HR-HPV–driven head and neck cancers (HNC), particularly oropharyngeal cancers (OPC, or throat cancers). Investigators have determined that HR-HPV DNA can be detected in saliva in most patients with HPV-driven OPC at the time of diagnosis.

HR 40

Pfizer seeks approval from US FDA for Covid-19 treatment

Pharmaceutical Technology

The latest filing is based on non-clinical and clinical data for Paxlovid and also comprised data from the Phase II/III EPIC-HR clinical trial.

HR 83

“Closest black hole” system found to contain no black hole

Scienmag

In 2020 a team led by European Southern Observatory (ESO) astronomers reported the closest black hole to Earth, located just 1000 light-years away in the HR 6819 system.

Enhertu significantly improved both progression-free and overall survival in DESTINY-Breast04 trial in patients with HER2-low metastatic breast cancer

The Pharma Data

Up to 55% of all patients with breast cancer have tumours with a HER2 IHC score of 1+, or 2+ in combination with a negative ISH test, a level of HER2 expression not currently eligible for HER2-targeted therapy.1,2 HER2-low expression occurs in both HR-positive and HR-negative disease.3.

HR 52

The power of similarities to accelerate antiviral development for COVID-19

Elsevier

In April 2020, I wrote a blog post entitled “ Exploiting similarities between SARS-CoV-2 and other viruses to accelerate vaccine and therapy development ,” where I described research areas leveraging genetic and phenotypic similarities between SARS-CoV- 2 and other known viruses.

Enhertu granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer

The Pharma Data

1-4 Low HER2 expression occurs in both HR-positive and HR-negative disease. 6 Currently chemotherapy remains the only treatment option for patients with HR-positive tumours following progression on endocrine (hormone) therapy.

HR 52

BioTalent Canada Named as a “Best Workplace for Women” for 2022

BioTech 365

BioTalent Canada Named as a “Best Workplace for Women” for 2022 BioTalent Canada Named as a “Best Workplace for Women” for 2022 OTTAWA, Ontario–(BUSINESS WIRE)–#HR–BioTalent Canada is honoured to mark International Women’s Day by being recognized as a 2022 Best … Continue reading → Business Wire

HR 52

Ribociclib added to endocrine therapy extends survival in postmenopausal patients with metastatic breast cancer

Scienmag

A study led by researchers from The University of Texas MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.

HR 63

First-line CDK 4/6 inhibition shows overall survival benefit for metastatic breast cancer

Scienmag

1) Credit: ESMO Lugano, Switzerland, 19 September 2021 – Adding a CDK 4/6 inhibitor to first-line hormonal treatment prolongs survival by one year for postmenopausal women with hormone receptor (HR) […].

$1.5M Wage Subsidy to Break Down Walls for Barriered Youth in Canada’s Bio-Economy

BioTech 365

Wage Subsidy to Break Down Walls for Barriered Youth in Canada’s Bio-Economy OTTAWA, Ontario–(BUSINESS WIRE)–#HR–Today, BioTalent Canada announced the relaunch of its successful Career Starter wage … Continue reading → Business Wire

HR 52

Pharma’s outdated hiring practices

World of DTC Marketing

One of the people I work with has more than 20 years of experience as an HR VP. Yet, when she was contacted about taking over a small companies HR department, she declined because the hiring process consisted of too many interviews over too long a period.

Akoya Biosciences Appoints Marilee Moy as Chief People Officer

BioTech 365

Moy brings 30 years of HR leadership experience at high-performing companies MARLBOROUGH, Mass., Akoya Biosciences Appoints Marilee Moy as Chief People Officer Akoya Biosciences Appoints Marilee Moy as Chief People Officer Ms. 20, 2022 (GLOBE NEWSWIRE) — Akoya Biosciences, … Continue reading → GlobeNewswire

HR 40

Biopsy Reclassification Risk in Prostate Cancer Examined

The Pharma Data

or greater (hazard ratio [HR], 3.37), percentage biopsy cores positive (HR, 1.27), and high genomic score (HR, 2.81) at first surveillance biopsy as well as at one to three years, after adjusting for other factors. or greater (HR, 2.36) and PSA kinetics (HR, 2.19).

HR 52

Biotech Career Prospects Improved with New BioTalent Canada Technical Skills Training

BioTech 365

OTTAWA, Ontario–(BUSINESS WIRE)–#HR–BioTalent Canada and the Stem Cell Network today announced the launch of BioTalent Canada’s new national bilingual online “Technical Skills Fundamentals Training Program” that will help students transition successfully to the bio-economy workforce.

HR 52

The Stem Cell Network Joins BioTalent Canada’s National Partnership Network

BioTech 365

OTTAWA, Ontario–(BUSINESS WIRE)–#HR–BioTalent Canada today announced the Stem Cell Network (SCN) has joined on as a Gold Plus Partner.

HR 52

Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET Trial Evaluating Neratinib in HER2-Positive, Hormone Receptor-Positive, Early Stage Breast Cancer

BioTech 365

NASDAQ: PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive, hormone receptor-positive (HR+), early stage breast cancer (eBC) from the Phase III ExteNET trial were … Continue reading → Business Wire

HR 52

Passing the trash

World of DTC Marketing

When she brought it up to HR, the VP immediately went to the President, and John was asked to leave. I’ve seen some new energy and thinking taking root in some big pharma companies.